

LGBT Bar  
2020 Lavender Law Conference and Career Fair

**Swipe Right: Health Care Privacy in the Era of Smart Devices and Digital Health**

CLE Materials

Cameron Faber  
General Counsel  
Los Angeles LGBT Center  
[cfaber@lalgbtcenter.org](mailto:cfaber@lalgbtcenter.org)  
(213) 993-7452

Greg Fosheim  
Associate Attorney  
McDermott Will & Emery LLP  
[gfosheim@mwe.com](mailto:gfosheim@mwe.com)  
(312) 984-7511

Sumaya Noush  
Associate Attorney  
Faegre Drinker Biddle & Reath LLP  
[Sumaya.noush@faegredrinker.com](mailto:Sumaya.noush@faegredrinker.com)  
(312) 569-1268

Colin Wright  
Intellectual Property & Technology Counsel  
Landis+Gyr  
[Colin.Wright@landisgyr.com](mailto:Colin.Wright@landisgyr.com)  
(678) 258-1412

## **Swipe Right: Health Care Privacy in the Era of Smart Devices and Digital Health**

Laws to protect health information privacy and confidentiality are largely designed to protect against the unauthorized access to, use of, and disclosure of personal health information. A variety of state and federal laws attempt to make health information secure from hackers, thieves, and rogue health care employees.

The individuals seeking disclosure from physicians might include law enforcement, public health authorities, relatives of the patient, employers, insurance companies, schools, and lawyers.

### **I. The Health Insurance Portability and Accountability Act**

The Health Insurance Portability and Accountability Act (“HIPAA”), [42 U.S.C. §§ 300gg, 300gg-1](#), and [300gg-2](#), enacted in 1996, contains a provision that required Congress to enact privacy legislation by August 21, 1999. If Congress failed to do so, the law directed the Secretary of Health and Human Services (“HHS”) to promulgate regulations for the privacy of medical information. Following unsuccessful attempts to pass federal legislation, proposed regulations were issued in November 1999. After considering over 50,000 comments, the final regulations were issued on December 28, 2000 and had a compliance date of April 2003. The regulations appear at [45 C.F.R. Parts 160 and 164](#).

#### **A. Who’s Covered by the HIPAA Privacy Rule?**

The HIPAA Privacy Rule (the “Privacy Rule”) applies to health plans, health care clearinghouses, and to any health care provider who transmits health information in electronic form in connection with transactions for which the Secretary of HHS has adopted standards under HIPAA (the “Covered Entities”).

Health care providers often assume they must comply with HIPAA; however, for many, HIPAA does not apply. If a health care provider does not submit electronic claims for reimbursement, that health care provider is most likely not subject to HIPAA. Massage therapists, estheticians, acupuncturists, naturopaths, and physicians who practice concierge medicine generally are not subject to HIPAA because they provide services that are not covered by a patient’s insurance plan and thus, these providers do not submit claims electronically.<sup>1</sup>

A health plan includes health insurance companies, health maintenance organizations (HMO), governmental insurance (e.g., Medicare, Medicaid, Tricare), and employer-sponsored health plans. Self-insured companies with fewer than 50 employees may be exempt from HIPAA; however, we strongly recommend engaging experienced health care counsel if you have questions about HIPAA compliance for self-insured companies.

A health care clearinghouse is an independent third-party entity that forwards claims to payors after checking for errors and verifying that the information is compatible with the payor software and converting such information when necessary. The clearinghouse can also operate to return

---

<sup>1</sup> Note that state data privacy laws may still apply to any person or entity in possession of personally-identifiable information.

that information from the payor to the provider by re-converting it to the provider's preferred format.

### **B. What Information is Protected?**

The Privacy Rule protects all individually identifiable health information held or transmitted by a Covered Entity or its business associate, in any form or media, whether electronic, paper, or oral. The Privacy Rule calls this information "protected health information" ("PHI").

### **C. Basic Principle for Uses and Disclosures**

A primary purpose of the Privacy Rule is to define and limit the circumstances in which an individual's PHI may be used or disclosed by Covered Entities. A Covered Entity may not use or disclose PHI, except either (1) as the Privacy Rule permits, or (2) as the individual who is the subject of the information (or their personal representative) authorizes in writing.

### **D. Required Disclosures**

A Covered Entity must disclose PHI in only two situations: (1) to individuals (or their personal representatives) specifically when they request access to, or an accounting of disclosures of, their PHI, and (2) to HHS when it is undertaking a compliance investigation or review or enforcement action.

### **E. Permitted Uses and Disclosures**

A Covered Entity is permitted, but not required, to use and disclosure PHI, without an individual's authorization, for the following purposes or situations:

1. To the individual (unless required for access or accounting of disclosures);
2. Treatment, Payment, and Health Care Operations;
3. Opportunity to Agree or Object;
4. Incident to an otherwise permitted use and disclosure;
5. Public interest and Benefit Activities; and
6. Limited Data Set for purposes of research, public health, or health care operations.

Covered Entities may rely on professional ethics and best judgments to decide which of these permissive uses and disclosures to make.

### **F. Family and HIPAA**

The HIPAA Privacy Rule contains several provisions that recognize the integral role that family members, such as spouses, often play in a patient's health care. For example, the Privacy Rule allows Covered Entities to share information about the patient's care with family members in various circumstances. It also generally requires Covered Entities to treat an individual's personal representative, who may be a spouse, as the individual, for purposes such as exercising the individual's rights under the Privacy Rule, including the right to access the individual's health information. In addition, the Privacy Rule provides protections against the use of genetic information about an individual, which also includes certain information about family members of the individual, for underwriting purposes.

The definition of *family member* in the Privacy Rule at [45 CFR 160.103](#) includes the terms *spouse* and *marriage*. The term *marriage* includes all lawful marriages. A lawful marriage is any marriage sanctioned by a state, territory, or a foreign jurisdiction as long as a U.S. jurisdiction would also recognize the marriage performed in the foreign jurisdiction. The term *spouse* includes all individuals who are in lawful marriages without regard to the sex of the individuals. The term *family member* includes lawful spouses and dependents of all lawful marriages. In addition, the terms *marriage*, *spouse*, and *family member* apply to all individuals who are legally married, regardless of where they live or receive health care services.

- The definition of a *family member* is relevant to the application of [§164.510\(b\)](#) regarding permitted uses and disclosures of PHI related to another person's involvement in an individual's care, and for making notifications about the individual's location, general condition, or death. Under certain circumstances, Covered Entities are permitted to share an individual's protected health information with a family member of the individual. Legally married spouses are family members for the purposes of applying this provision.
- The definition of a *family member* is also relevant to the application of [§164.502\(a\)\(5\)\(i\)](#) regarding the uses and disclosures of genetic information for underwriting purposes. This provision prohibits health plans, other than issuers of long-term care policies, from using or disclosing genetic information for underwriting purposes. For example, health plans may not use information regarding the genetic tests of a family member of the individual, or the manifestation of a disease or disorder in a family member of the individual, in making underwriting decisions about the individual. This includes the genetic tests of a lawful spouse of the individual, or the manifestation of a disease or disorder in the lawful spouse of the individual.

## **G. Personal Representative**

Subject to limited exceptions, the Privacy Rule at [45 CFR 164.502\(g\)](#) requires Covered Entities to treat an individual's *personal representative* as the individual with respect to uses and disclosures of the individual's protected health information and for purposes of exercising the individual's rights under the Privacy Rule. For example, a personal representative of an individual is able to review and obtain a copy of the individual's medical record or authorize disclosures of protected health information. In determining who is considered a personal representative, and thus able to act on behalf of an individual and exercise the individual's rights under HIPAA, the Privacy Rule generally looks to state laws governing which persons have authority to act on behalf of an individual in making decisions related to health care.

Under the Privacy Rule, if a state provides legally married spouses with health care decision making authority on behalf of one another, a Covered Entity is required to recognize the lawful spouse of an individual as the individual's personal representative without regard to the sex of the spouses.

OCR has issued a [FAQ](#) explaining that, under the HIPAA Privacy Rule, disclosures to a loved one who is not married to the patient or is not otherwise recognized as a relative of the patient under applicable law generally are permitted under the same circumstances and conditions as disclosures to a spouse or other person who is recognized as a relative under applicable law. The FAQ, while applicable in a variety of circumstances, was developed in large part to address confusion following the 2016 Orlando nightclub shooting about whether and when hospitals may share

protected health information with patients' loved ones. The FAQ emphasizes that HIPAA does not limit any permitted disclosures based on the sex or gender identity of the recipient of the information.

## H. Authorized Uses

A Covered Entity must obtain the individual's written authorization for any use or disclosure of PHI that is not for treatment, payment, or health care operations or otherwise permitted or required by the Privacy Rule. A Covered Entity may not condition treatment, payment, enrollment, or benefits eligibility on an individual granting an authorization, except in very limited circumstances.

Examples of disclosures that would require individual authorization include disclosures to a life insurer for coverage purposes, disclosure to an employer of the results of a pre-employment physical or lab test, or disclosures to a pharmaceutical firm for their own marketing purposes.

All authorizations must be in plain language and contain specific information regarding the information to be disclosed or used, the person(s) disclosing and receiving the information, expiration, right to revoke in writing, and other data.

## I. Business Associates

The HIPAA Privacy Rule recognizes that health care providers and health plans cannot carry out all of their functions alone. Thus, covered entities are permitted to disclose protected health information to "business associates" upon obtaining satisfactory assurance that the business associate will use PHI only for the purposes for which it was engaged, will safeguard PHI from misuse, and will assist the covered entity with compliance with its duties when so required by the Privacy Rule.

Some examples of business associates are as follows:

- A third party claims processor that submits bills to insurance on behalf of a provider;
- A CPA that provides accounting services to a physician;
- A consultant who performs utilization reviews for a hospital;
- A healthcare clearinghouse that translates non-standard claims forms into a form that can be processed by a payor;
- Medical transcriptionists;
- Pharmacy benefits managers;
- **Attorneys who provide legal services to health care providers that may require access to PHI.**

Best practice is for a covered entity to enter into a Business Associate Agreement with a business associate. This agreement must contain all of the elements specified at [45 CFR § 164.504\(e\)](#). A sample business associate agreement made available by the HHS Office of Civil Rights is attached as [Appendix A](#).

A few common situations do not give rise to the need for a business associate agreement and PHI may be disclosed to the person or entity without the individual's authorization:

- Disclosures necessary for treatment of an individual;
  - Hospital may refer a patient to an outside specialist and transmit medical charts for treatment purposes without entering into a business associate agreement.
  - Physicians are not required to enter into business associate agreements with laboratories as a condition of disclosing PHI for the treatment of an individual.
  - Hospital laboratories do not need business associate agreements with outside reference laboratories for treatment of an individual.
- Disclosures to a health plan sponsor (such as an employer) by a group health plan, health insurance company, or HMO that provides benefits or coverage for the group health plan;
- Disclosures by a public benefit plan (e.g. Medicare) to another agency that is able to assist with determining eligibility or enrollment (e.g., Social Security Administration);
- Disclosures by a provider to a health plan for payment purposes;
- Persons in an organization (e.g., custodians; electricians) whose functions do not involve access to PHI and any encounters with PHI would be incidental;
- Conduits for PHI, such as postal workers and couriers;
- Between covered entities that participate in an Organize Health Care Arrangement as pertaining to disclosures that related to joint health care activities;
- When a group health plan purchases insurance from an insurance company or an HMO;
- When PHI is disclosed for research purposes, either with patient authorization, pursuant to a waiver, or as a limited data set; and
- Financial institutions processing funds for payment for health care or health plan premiums.

## **J. Minimum Necessary**

A central aspect of the Privacy Rule is the principle of “minimum necessary” use and disclosure. A Covered Entity must make reasonable efforts to use, disclose, and request only the minimum amount of PHI needed to accomplish the intended purpose of the use, disclosure, or request. A Covered Entity must develop and implement policies and procedures to reasonably limit uses and disclosures to the minimum necessary. When the minimum necessary standard applies to a use or disclosure, a Covered Entity may not use, disclose, or request the entire medical record for a particular purpose, unless it can specifically justify the whole record as the amount reasonably needed for the purpose.

The minimum necessary rule is not imposed in the following circumstances:

1. Disclosure to or a request by a health care provider for treatment;
2. Disclosure to an individual who is the subject of the information (or their personal representative);
3. Use or disclosure made pursuant to an authorization;
4. Disclosure to HHS for complaint investigation, compliance review, or enforcement;
5. Use or disclosure that is required by law; or
6. Use or disclosure required for compliance with the HIPAA Transaction Rule or other HIPAA Administrative Simplification Rules.

## **K. Preemption**

In general, state laws that are contrary to the Privacy Rule are preempted by the federal requirements. “Contrary” means it would be impossible for a Covered Entity to comply with both state and federal requirements, or that the provision of state law is an obstacle to accomplishing the full purposes and objectives of HIPAA. The Privacy Rule provides these exceptions to this general rule of federal preemption:

1. Relate to the privacy of individually identifiable health information and provide greater privacy protections or privacy rights with respect to such information;
2. Provide for the reporting of disease or injury, child abuse, birth, or death, or for public health surveillance, investigation, or intervention, or;
3. Require certain health plan reporting, such as for management or financial audits.

## **L. Enforcement and Noncompliance**

The Privacy Rule provides processes for persons to file complaints with HHS, describes the responsibilities of Covered Entities to provide records and compliance reports and to cooperate with compliance reviews and investigations.

HHS may impose civil money penalties on a Covered Entity up to \$50,000 per failure to comply with a Privacy Rule requirement, depending on the violation category, as described below. That penalty may not exceed \$1.5 million per year for multiple violations of the identical Privacy Rule requirement in a calendar year. DOJ may impose criminal penalties depending on the severity and degree of scienter involved with non-compliance.

### Civil monetary penalties

Tier	Penalty
1. Covered entity or individual did not know (and by exercising reasonable diligence would not have known) the act was a HIPAA violation.	\$100-\$50,000 for each violation, up to a maximum of \$1.5 million for identical provisions during a calendar year
2. The HIPAA violation had a reasonable cause and was not due to willful neglect.	\$1,000-\$50,000 for each violation, up to a maximum of \$1.5 million for identical provisions during a calendar year
3. The HIPAA violation was due to willful neglect but the violation was corrected within the required time period.	\$10,000-\$50,000 for each violation, up to a maximum of \$1.5 million for identical provisions during a calendar year
4. The HIPAA violation was due to willful neglect and was not corrected.	\$50,000 or more for each violation, up to a maximum of \$1.5 million for identical provisions during a calendar year

### Criminal penalties

Tier	Potential jail sentence
Unknowingly or with reasonable cause	Up to one year
Under false pretenses	Up to five years
For personal gain or malicious reasons	Up to ten years

### M. Can individuals use HIPAA to bring a private action?

To-date, no federal court has found that HIPAA supports a private right of action. Recently, the District Court of the District of Columbia granted a defendant's motion to dismiss a suit that alleged the defendant failed to protect the plaintiff's privacy and confidentiality in violation of HIPAA. In Lee-Thomas v. LabCorp., the plaintiff alleged that the defendant's practice of entering medical information on a computer-intake station failed to properly shield her information from public view. The court granted the defendant's 12(b)(6) motion, stating that "the language of the [HIPAA] statute specifically limits enforcement action to HHS and individual states' attorneys general" (citing 42 U.S.C. §§ 1620d-5 to d-6 and citing several other district courts that dismissed private causes of action). (Lee-Thomas v. LabCorp., 316 F. Supp. 3d 471 (DDC 2018)).

However, at least one state supreme court has held that non-compliance with HIPAA may be indicative of negligence and/or breach of contract under state data privacy provisions. In Byrne v. Avery, the Connecticut Supreme Court stated that "to the extent it has become the common practice for Connecticut health care providers to follow the procedures required under HIPAA in rendering services to their patients, HIPAA and its implementing regulations may be utilized to inform the standard of care applicable to such claims arising from allegations of negligence in the disclosure of patients' medical records pursuant to a subpoena." Under that framework, the court held that "a duty of confidentiality arises from the physician-patient relationship and that unauthorized disclosure of confidential information obtained in the course of that relationship for the purpose of treatment gives rise to a cause of action sounding in tort against the health care

provider, unless the disclosure is otherwise allowed by law.” (Byrne v. Avery Ctr. For Obstetrics & Gynecology, P.C., 327 Conn. 540 (2018)).<sup>2</sup> Whether HIPAA is a viable grounds for establishing a standard of care is yet to be determined and likely will depend on how state courts and legislatures establish privacy protections under state laws.

#### **N. HIPAA and Wearable Technology**

As previously discussed, HIPAA applies to Covered Entities and Business Associates. Wearable technology vendors may not necessarily fall into either category, and data collected via wearable technology platforms may not be subject to the Security Rule. For example, a FitBit may be tracking steps and measuring heart rate, but the data that such a device collects is not protected by HIPAA, because there is no Covered Entity or Business Associate relationship. Conversely, if a healthcare provider instructs a patient to download a wearable technology application that monitors the patient’s health data, and that health data is transmitted and incorporated into the patient’s electronic health record, and if the application developer receives money from the healthcare provider for the digital service, then the developer is generating, collecting, storing, and sharing PHI on behalf of a Covered Entity, thereby making the developer a Business Associate who is subject to HIPAA.

In November 2019, Senators Bill Cassidy (R-LA) and Jacky Rosen (D-NV), introduced Senate Bill 2885 – Stop Marketing and Revealing the Wearables and Trackers Consumer Health (SMARTWATCH) Data Act. The SMARTWATCH Act would be an important piece of legislation to protect digital health procured from wearable technology in that it prohibits any entity that collects consumer health information from transferring, selling, sharing, or allowing access to any consumer health information if the primary purpose is for profit or for other commercial purposes. The SMARTWATCH Act was referred to the Committee on Health, Education, Labor and Pensions. This is one of the first efforts by Congress to update the nation’s laws to address wearable technology.

## **II. Distinguishing Genetic Privacy from General Notions of Medical Privacy**

What makes genetic information different from other sensitive medical information? George J. Annas, world famous bioethicist, health care lawyer and policy advocate, is one of the leading academic voices in support in support of the argument that genetic information is more powerfully private than other types of information. It is information about us, but not just about us. It is information about our parents, siblings, and children. It is also information that is very important for private decision-making: who to marry, whether or not to have a child, whether or not to undergo prenatal testing, and the future health of your child. It is also information about our likely future health. All of our genetic information is contained in the nucleus of each one of our cells. So far, genetic exceptionalism has been criticized in peer-reviewed literature, but the approach has

---

<sup>2</sup> An Ohio state court has also considered similar tort-based causes of action that used HIPAA as the standard of care. In Sheldon v. Kettering Health Network, the Ohio Court of Appeals held that HIPAA does not authorize a private right of action and “an administrative rule does not constitute negligence *per se*; however such a violation may be admissible as evidence of negligence.” 40 N.E. 661, 674 (Ohio Ct. App. 2015).

been adopted by legislatures where laws have generally addressed genetics separately from other health issues as uniquely private.

The Genetic Information Nondiscrimination Act (GINA) was signed into law on May 21, 2008 by President George W. Bush. GINA protects individuals against discrimination based on their genetic information in health coverage and in employment. GINA is divided into two sections, or Titles. Title I of GINA prohibits discrimination based on genetic information in health coverage. Title II of GINA prohibits discrimination based on genetic information in employment.

### **A. Health Coverage**

The Department of Treasury, the Department of Labor, and the Department of Health and Human Services collectively promulgated regulations to implement Title I of GINA. (74 Fed. Reg. 51664, Oct. 7, 2009). Title I of GINA makes it unlawful for health insurers to request, require, or use genetic information to make decisions about:

- Your eligibility for health insurance
- Your health insurance premium, contribution amounts, or coverage terms

**This means it is deny you coverage or determine your payment obligations based on a genetic test result or family history.**

In addition, GINA prohibits your health insurer from:

- Considering family history or a genetic test result to be a pre-existing condition
- Requiring that you have a genetic test (or even asking you to do so)
- Using any genetic information to discriminate against you, even if they did not mean to collect it

Importantly, GINA does not prohibit health insurance companies from making coverage decisions based on your current health status, including manifestations of disease due to genetic factors. Rather, GINA prohibits discrimination based on a genetic predisposition to a disease that has not manifested. Once a person becomes symptomatic, GINA no longer offers protection. For example, an insurance company cannot raise premiums or deny coverage because a person has a positive genetic test for Huntington disease. However, once that person shows signs and symptoms and is diagnosed with the disease, then GINA does not prohibit insurance companies from using the diagnosis to make coverage determinations.

### ***What health insurance does GINA protect?***

GINA generally applies to health insurance that you receive through your employer or for health insurance that individuals purchase on their own. GINA also applies to Medicare and any insurance plans that are available to supplement Medicare beneficiaries' plans. GINA does not offer protection to individuals who obtain health insurance from the Indian Health Service, the Federal Employees Health Benefits Plans, or Tricare; nor does it protect against genetic

information discrimination in other forms of insurance, such as life, disability, or long-term care insurance.

***Can my insurance company require me to undergo genetic testing or request my test results?***

Generally, insurers are prohibited from requesting or requiring genetic information about applicants or beneficiaries. The only exception to this generality is if genetic information is a key criterion for determining whether to pay for a requested test, treatment, or procedure in order to justify medical need. In such a situation, insurance companies must request only the minimum information necessary to make a determination, and any information that is received must not be further used to discriminate against a beneficiary.

**B. Employment**

GINA prohibits employers from using your genetic information in the following ways:

- To make decisions about hiring, firing, promotion, pay, privileges or terms
- To limit, segregate, classify, or otherwise mistreat an employee

**This means it is unlawful for your employer to use family health history and genetic test results in making decisions about your employment.**

It is also against the law for an employer to request, require, or purchase a potential or current employee's genetic information or that of his or her family members. There are a few exceptions to when an employer can legally have your genetic information. If an employer does have the genetic information of an employee, the employer must keep it confidential and in a separate medical file.

***What is genetic information? ([29 CFR 1635.3](#))***

GINA defines genetic information to include the following:

- Your individual genetic tests;
- Your family members' genetic tests (including dependents and up to a fourth-degree relative);
- Family medical history or manifestation of diseases in family members;
- Any requests by an individual or a family member for genetic services or participation in clinical research studies that includes genetic services as part of the research;
- Genetic information of a fetus carried by an individual or a pregnant woman who is a family member of an individual; and
- Genetic information of any embryo legally held by an individual or a family member using assisted reproductive technology.

GINA does not include the following information:

- Sex;

- Age; or
- Information about race or ethnicity that is not derived from a genetic test, where “genetic test” is any test that assesses genotypes, mutations, or chromosomal changes

A 2012 case from Virginia is illustrative regarding genetic information. The plaintiff alleged that he was terminated from his employment in part because he disclosed his wife’s multiple sclerosis diagnosis and prognosis on a health insurance questionnaire regarding his family’s general medical conditions and medications. A month later, an office manager asked when his wife was diagnosed and about her prognosis. Three days later, the plaintiff was terminated without explanation. Addressing the plaintiff’s GINA claims, the Western District of Virginia clarified that “a consistent history of an inheritable disease in an individual’s family may be viewed to indicate that the individual himself is at an increased risk for that disease; [h]owever, the fact that an individual family member merely has been diagnosed with a disease or disorder is not considered ‘genetic information’ if ‘such information is taken into account only with respect to the individual in which such disease or disorder occurs and not as genetic information with respect to any other individual’.” Poore v. Peterbilt of Bristol, LLC, 852 F. Supp. 2d 727, 731 (W.D. Va. 2012) (quoting 2008 U.S.C.C.A.N 101, 105-106). The court explained that the plaintiff may have a claim under the Americans with Disabilities Act, but to state a claim under GINA, the plaintiff would have needed to allege that his employer used his wife’s diagnosis “to forecast the tendency of any other individual to contract multiple sclerosis.” Poore at 731.

Similarly, a diagnosis of HIV is not genetic information protected by GINA. In a North Carolina case, a plaintiff claimed that his employer wrongfully disclosed confidential information about the plaintiff’s HIV status to coworkers and customers in violation of GINA. The court stated that “Neither Plaintiff’s HIV diagnosis, kidney failure, nor viral gastroenteritis constitute genetic information about a manifested disease or disorder [and] an HIV test is not an example of a genetic test.” Hoffman v. Family Dollar Stores, Inc., 99 F. Supp. 3d 631, 637 (referencing Background Information for EEOC Final Rule on Title II of GINA, *available at* <http://www.eeoc.gov/laws/regulations/gina-background.cfm>).

***What employers must comply with GINA?***

A GINA-covered entity is an employer, employing office, employment agency, labor organization or joint labor-management committee with at least 15 employees for each working day in each of 20+ calendar weeks in the current or preceding calendar year. ([29 CFR 1635.2\(c\)\(1\)](#)). A covered entity’s actions must apply to its workforce in their capacity as employees, members of a labor organization, or a participant in an apprentice program. This means that GINA would not apply to a hospital employee undergoing a medical examination at its employer’s facility for reasons unrelated to employment. GINA also would not apply to law enforcement employers investigating criminal conduct.

***When can my employer know my genetic information?***

The most common reasons for an employer to know of an employee’s genetic information are somewhat predictable. Even in these situations, the employer cannot use any genetic information to discriminate against an employee.

- Inadvertent knowledge: If an employer learns about an employee’s genetic information accidentally or overhears a conversation about a sick child or a test result, there is a GINA violation.
- Public information: If an employer learns about genetic information through the newspaper or other publicly available resources, the employer has not violated GINA.
- Family and Medical Leave Act (FMLA): If an employee needs to take time away from work to care for a sick family member, questions and forms required to approve such leave may ask about genetic information if pertinent.
- Voluntary health services: Employers can offer voluntary health or genetic services, including wellness programs. If these programs are truly voluntary, then forms, questionnaires, and health care providers overseeing the programs may ask for health histories, including genetic information.

Until recently, employers were permitted to offer employees an inducement to provide his or her current health status information as part of a health risk assessment administered in connection with an employee-sponsored wellness program. As outlined above, GINA allows employers to ask health-related questions and to conduct medical examinations if doing so is voluntary for employees. In 2017, AARP challenged the “voluntary” nature of employee wellness program financial incentives, arguing that such incentives (up to 30% of the cost of health insurance coverage) was coercive. Ultimately, the DC District Court, while affording Chevron deference, determined that EEOC failed to make a case that 30% incentives satisfy the “voluntary” requirement under GINA, and the Court remanded the matter to EEOC to revise its rules (See AARP v. EEOC, 292 F. Supp. 3d 238 (DDC 2017), *available at* [https://ecf.dcd.uscourts.gov/cgi-bin/show\\_public\\_doc?2016cv2113-47](https://ecf.dcd.uscourts.gov/cgi-bin/show_public_doc?2016cv2113-47)). In December 2018, EEOC published a final rule removing the provision that allowed employers to offer financial incentives to employees that participate in wellness programs. ([83 Fed. Reg. 65296 \(Dec. 20, 2018\)](https://www.federalregister.gov/documents/2018/12/20/2018-26296)). Employers may still ask employees about genetic information as part of employee wellness programs; however, the provision of information must be voluntary, meaning the employer neither requires the individual to provide such information nor penalizes those who choose not to provide it. ([29 CFR § 1635.8\(b\)\(2\)\(i\)\(B\)](https://www.ecfr.gov/current/title-29/chapter-I/subchapter-B/part-1635/subpart-1635.8/section-1635.8(b)(2)(i)(B))).

***What can lawyers do to protect employers from inadvertent disclosures of genetic information?***

The Title II regulations provide sample language that covered employers may want to include in any contract that may result in disclosures of medical information. With this language, any receipt of genetic information along with medical information will be deemed inadvertent:

*The Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits employers and other entities covered by GINA Title II from requesting or requiring genetic information of an individual or family member of the individual, except as specifically allowed by this law. To comply with this law, we are asking that you not provide any genetic information when responding to this request for medical information. ‘Genetic information’ as defined by GINA, includes an individual’s family medical history, the results of an individual’s or family member’s genetic tests, the fact that an individual or an individual’s family member sought or received genetic services, and genetic information of a fetus carried by an*

*individual or an individual's family member or an embryo lawfully held by an individual or family member receiving assistive reproductive services.*

See [29 CFR § 1635.8\(b\)\(1\)\(B\)](#).

***Can my employer give stipends, rewards and discounts on my insurance if I wear a device that track my movement that also gives them to my genetic information?***

As previously described, an employer cannot request, require disclosure of or purchase genetic information; however, an employer can offer voluntary health or genetic services to employees or their family members as part of a wellness program. 29 CFR § 1635.8(b)(2). Because GINA is an anti-discrimination law rather than a privacy law, an employer who uses genetic information disclosed through a wearable device may be liable for discrimination if information from the wearable device related to an employee's genetic history was factored into hiring or firing decisions. But there currently is no law that would prohibit an employer incentivizing employees to wear fitness tracking devices that also provide access to genetic information.

### **III. Confidentiality of Alcohol and Drug Abuse Patient Records<sup>3</sup>**

The privacy provisions in [42 CFR Part 2](#) were motivated by the understanding that stigma and fear of prosecution might dissuade persons with substance use disorders from seeking treatment. To add an extra layer of protection on these records, the regulations outline under what limited circumstances information about a patient's treatment may be disclosed with and without the patient's consent.

The Substance Abuse and Mental Health Services Administration (SAMHSA) released a final rule (the "Final Rule") in January 2017 modernizing the confidentiality requirements for substance use disorder (SUD) patient records (also known as 42 CFR Part 2, or "Part 2"). Twelve takeaways from the Final Rule and subsequent SAMHSA guidance are as follows:

#### **1) SAMHSA has clarified the definition of "Part 2 Program."**

The confidentiality requirements of Part 2 apply to Part 2 Programs, which generally include SUD programs (a) conducted, licensed, or funded by a federal department or agency; or (b) that are tax exempt or receive tax deductions for contributions ((a) and (b) are collectively referred to as "Federal Support"), and (c) which hold themselves out as providing and actually do provide SUD diagnosis, treatment, or referral for treatment. SAMHSA has clarified that a Part 2 Program can be (i) an individual or entity; (ii) an identified unit within a general medical facility (e.g., hospital, trauma center, or federally qualified health center); or (iii) medical personnel or staff within a general medical facility whose primary function is SUD diagnosis, treatment or referral. In each instance, the Program must receive Federal Support and hold itself out and actually provide SUD services.

---

<sup>3</sup> Material in this section is taken in part from Breuer, JR and Fosheim, GE, *Top 10 Takeaways from SAMHSA's Recent Update of Substance Use Disorder Confidentiality Regulations*, 3 PRATT'S PRIVACY & CYBER SECURITY L. REPORT 185 (2017); and Breuer, JR and Fosheim, GE, *SAMHSA Continues to Refine Part Two Regulations* (available at <https://www.drinkerbiddle.com/insights/publications/2018/01/samhsa-continues-to-refine-part-two-regulations>).

## **2) SAMHSA recognizes the growing list of mind-altering substances.**

Previously, Part 2 applied to disclosures that “would identify a patient as an alcohol or drug abuser.” Now, Part 2 applies to SUDs, which are defined as “a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems such as impaired, control, social impairment, risky use, and pharmacological tolerance and withdrawal.” The definition does not include tobacco or caffeine use. In commentary, SAMHSA provides examples such as alcohol, cannabis, hallucinogens, inhalants, opioids, sedatives, hypnotics, anxiolytics, and stimulants.

## **3) A “Treating Provider Relationship” may exist prospectively.**

To better illustrate the consent requirements (described in numbers 4-6 below), SAMHSA defined a “treating provider relationship” to include the traditional, voluntary physician-patient relationship where an in-person visit has already occurred. However, recognizing that some SUD patients are involuntarily confined, it expanded the definition to include situations where (i) the patient is, agrees to, or is legally required to be diagnosed, evaluated, and/or treated or agrees to accept consultation for a SUD condition; and (ii) the individual or entity undertakes or agrees to undertake diagnosis, evaluation, or treatment of or consultation with the patient for any SUD condition. As a result, Part 2 obligations may arise for providers even before an initial patient encounter occurs.

## **4) Broad consent is permissible for disclosures of Part 2 Program information to others with Treating Provider Relationships.**

A Part 2 Program must obtain patient consent to disclose Part 2 Program information to an entity with which the patient has a Treating Provider Relationship. The consent must be in writing (paper or electronic) and include:

- (i) The patient’s name;
- (ii) The Part 2 Program permitted to make the disclosure;
- (iii) The amount and kind of SUD-related information to be disclosed; and
- (iv) The name of the individual or entity that is to receive that information.

A sample patient consent is available at [Appendix B](#). Patients may also give broad consent for disclosure to classes of individuals or entities who may have future Treating Provider Relationships, even though their identity is not known at the time of consent. In this case, the consent must include a general description of the individual or entity, or class of individuals or entities to whom disclosure may be made. The consent must also inform the SUD patient of his or her rights to request and receive a list of individuals and entities to which their Part 2 Program information has been disclosed pursuant to a general description.

Tracking disclosures may prove to be burdensome to Part 2 Programs. Part 2 Programs are not allowed to use a broad or general consent until they have a methodology in place to track the disclosures necessary for a patient accounting.

**5) Specific consent is required for Part 2 Program disclosures outside of a Treating Provider Relationship.**

For a Part 2 Program to disclose SUD-related information to a third party outside of Treating Provider Relationship, the consent must contain each of the elements described in 4(i) through 4(iv) above. Each must be described with specificity and by name.

**6) Disclosure without consent is permissible only in very limited circumstances.**

SAMHSA outlined three circumstances in which patient consent is not required to disclose SUD-related records: (1) Bona fide medical emergencies; (2) Research; or (3) Audits.

Part 2 Programs may disclose SUD-related records to medical personnel to the extent necessary to meet a bona fide medical emergency in which the patient's consent cannot be obtained. In a medical emergency, the Program must immediately document, in writing: (i) the name of the recipient and their affiliation with a health care facility; (ii) the name of the disclosing party; (iii) the date and time of the disclosure; and (iv) the nature of the emergency. SAMHSA clarified that legal incapacity to consent may qualify in an involuntary commitment situation; however, if the patient refuses to consent and has legal capacity to do so, the situation cannot be deemed one in which consent cannot be obtained. SAMHSA plans to release additional guidance regarding medical emergencies that would be valid grounds to release SUD-related records.

Part 2 Programs may also disclose SUD information for the purpose of conducting scientific research if person with responsibility for disclosure determines that (i) the recipient is a covered entity or business associate under HIPAA and has obtained appropriate authorization or waiver from the patient; (ii) the recipient is subject to the human subjects protection Common Rule ([45 CFR Part 46](#)) and has obtained the patient's informed consent or an appropriate waiver or exemption; or (iii) both HIPAA and Common Rule compliance is met, when applicable. Researchers must not re-disclose patient information, may include data in research reports only in a non-identifiable aggregate form, must follow Part 2 storage requirements including destruction of SUD-data, and must retain the patient records in accordance with all applicable laws.

Finally, Part 2 Programs may disclose SUD information without patients' consent for audit or evaluation purposes. The Part 2 Program must determine that the recipient is qualified to audit the Program. Permitted auditors may include entities reviewing Part 2 Programs on behalf of Medicare, Medicaid, CHIP, or federally regulated accountable care organizations. The regulations regarding audit disclosures without consent are extremely complex. Part 2 Programs are encouraged to review the regulations carefully and consult with legal counsel.

**7) Part 2 Programs must have policies and procedures to prevent unauthorized users and disclosures of Program information.**

The Final Rule requires Part 2 Programs and lawful holders of Part 2 Program information to have formal policies and procedures in place to protect against unauthorized uses and reasonably anticipated threats or hazards to patients' identifying information. The policies and procedures must address (i) transferring, removing, destroying, and maintaining paper records; (ii) physical safeguards for paper records at workstations and cabinets; (iii) rendering patient identifying information in paper records non-identifiable or with a low risk of re-identification; (iv) creating,

receiving, maintaining and transmitting electronic records; (v) destroying electronic medical records and sanitizing storage media; (vi) using and accessing electronic medical records; and (vii) rendering patient identifying information in electronic records non-identifiable or with a low risk of re-identification. Notably, courts, law firms, family members and private citizens are not considered “lawful holders” for disclosure purposes and thus are not required to prepare policies and procedures.

**8) Part 2 may look, talk and smell like HIPAA, but it is not HIPAA.**

Many commenters suggested aligning Part 2 confidentiality requirements with HIPAA, proposing that Part 2 Program information be treated like psychotherapy notes under HIPAA. SAMHSA noted its attempts at such alignment in the Final Rule, but repeatedly reminded commenters that Part 2 provides more stringent federal protections than are required under other health privacy laws. This suggests that providers risk non-compliance by relying solely on their HIPAA policies to safeguard Part 2 Program patients’ privacy.

**9) Part 2 Programs must inform patients of their confidentiality rights and may not confirm or deny patient status.**

When patients are admitted to Part 2 Programs or as soon as practicable thereafter, that patient must receive paper or electronic notice of their rights under Part 2 Programs. The notice must include contact information and appropriate authorities for reporting Part 2 violations. In addition, Part 2 Programs are prohibited from issuing statements such as “an identified individual is not and has never been a patient.” One commenter illustrated how such statements could give rise to third-party expeditions when the Program answers with silence. Previously, the regulations did not restrict such a disclosure.

**10) SAMHSA has promulgated subsequent rulemaking since the Final Rule.**

In a final rule published on January 3, 2018, SAMHSA took further steps to modernize Part 2 and to align the regulations with the way health care is delivered in the United States. Specifically, SAMHSA:

1. Provided an option for an abbreviated redisclosure prohibition notice in recognition of electronic medical record (EMR) character limitations.
2. Established that lawful holders of Part 2 data may disclose such data to contractors, subcontractors and legal representatives for payment and health care operations-related purposes without specific consent.
3. Clarified that government entities funding Part 2 programs may have access to program information as necessary to conduct audits and evaluations without patient consent, and similarly may share Part 2 information with contractors, subcontractors and legal representatives for audit and evaluation purposes.

42 CFR § 2.32 requires disclosures made with SUD patients’ consent to include a lengthy written statement informing the recipient that the information may not be further disclosed without specific patient’s consent or as otherwise permitted by law. SAMHSA sought comments on whether an abbreviated notice should be permissible and, if so, the circumstances in which such notice might be appropriate.

After acknowledging that many EMR systems have internal codes, flags, pop-ups and other signifiers in place to protect health information under HIPAA and other privacy laws, SAMHSA discussed that an abbreviated notice may be useful primarily in EMRs with character-limited free-text fields (often 80 characters or fewer). In the final rule, however, SAMHSA declined to limit use of an abbreviated notice to EMR free-text fields. Instead, SAMHSA amended 42 CFR § 2.32 to allow lawful holders of Part 2 information to append the following redisclosure notice any time notice is required under the Part 2 regulations:

“42 CFR part 2 prohibits unauthorized disclosure of these records.”

Lawful users also may continue to use the longer redisclosure prohibition language found at 42 CFR § 2.32(a)(1). This language is provided in [Appendix C](#).

### **11) Authorized Disclosures for Payment and Health Care Operations Purposes**

42 CFR § 2.33 allows a Part 2 program to disclose SUD patient records upon obtaining the patient’s written consent to any person identified in the consent. SAMHSA proposed to permit disclosure of such information to contractors, subcontractors and legal representatives without patient consent for specifically identified payment and health care operations activities. In so doing, SAMHSA recognized the practical importance of allowing such disclosures rather than requiring Part 2 programs to list each contractor, subcontractor or legal representative on a consent form or to obtain new consents whenever a contractor is changed.

Although the final rule does not include the list of approved payment and operations activities in the regulations, SAMHSA includes in the preamble to the final rule the activities listed in [Table 1](#) below as non-exclusive examples of payment and health care operations for which disclosure without patient consent is permissible. Importantly, unlike HIPAA, “health care operations” under Part 2 do not include care coordination and case management activities. Nor does the final rule permit Part 2 programs to disclose Part 2 information to contractors, subcontractors and legal representatives for treatment, diagnosis or referral purposes. SAMHSA emphasized the importance of patient choice in disclosing information protected by Part 2 to health care providers with whom patients have direct contact.

Part 2 programs that wish to disclose Part 2 information to contractors, subcontractors or legal representatives for payment and health care operations purposes are required to have agreements in place with such third parties. The agreements must include provisions requiring compliance with Part 2 and must make clear that the contractor, subcontractor or legal representative is fully bound by the provisions of Part 2 and that unauthorized redisclosure is prohibited. Common contract language obligating “compliance with all applicable federal and state laws” will not suffice. We recommend that Part 2 programs include language similar to the following when entering into agreements with contractors, subcontractors and legal representatives to provide payment and/or health care operations support:

*“[Contractor] hereby acknowledges that it is fully bound by the provisions of 42 CFR Part 2 upon the receipt of any Part 2 program patient identifying information. 42 CFR Part 2 prohibits unauthorized disclosure of these records. [Contractor] shall implement all reasonable and appropriate safeguards to prevent unauthorized uses and disclosures of Part 2 program information and shall report any unauthorized uses, disclosures, or breaches of patient identifying information to [Lawful Holder].”*

Part 2 programs should ensure that any Part 2 program information disclosed is consistent with the purposes set forth in the patient’s consent and is comprised of only the minimal information necessary to meet the payment or health care operations need. Part 2 programs were required to incorporate the required language into their contracts by February 2, 2020.

<b>Table 1. Non-exclusive Examples of Payment and Health Care Operations</b>
<ul style="list-style-type: none"> <li>• Billing, claims management, collection activities, obtaining payment under a contract for reinsurance, claims filing, and related health care data processing.</li> <li>• Clinical professional support services (e.g., quality assessment; utilization management).</li> <li>• Patient safety activities.</li> <li>• Activities pertaining to (i) training of students and health care professionals; (ii) assessing practitioner competencies; (iii) assessing provider or health plan performance; or (iv) training of non-health care professionals.</li> <li>• Accreditation, certification, licensing or credentialing activities.</li> <li>• Underwriting, enrollment, premium rating and other activities relating to health insurance or health benefit contracts, and ceding, securing or placing a contract for reinsurance of risk relating to claims for health care.</li> <li>• Third-party liability coverage.</li> <li>• Activities related to fraud, waste and abuse.</li> <li>• Conducting and arranging for medical review, legal services and auditing functions.</li> <li>• Business planning and development, such as cost management and planning-related analyses, including formulary development and administration and developing or improving methods of payment or coverage policies.</li> <li>• Business management and general administrative activities.</li> <li>• Customer services, including providing data analyses for policy holders, plan sponsors and other customers.</li> <li>• Resolution of internal grievances.</li> <li>• Transactional needs, including sale, merger, consolidation or dissolution of an organization.</li> <li>• Determinations of eligibility for coverage and adjudication or subrogation of health benefit claims.</li> <li>• Risk adjusting amounts due based on enrollee health status and demographic characteristics.</li> <li>• Review of health care services for medical necessity, coverage under a health plan, appropriateness of care, or justification of charges.</li> </ul>

**12) Disclosures for the Purpose of Audits and Evaluations**

Many Part 2 programs receive financial support from federal, state or local governments. SAMHSA recognizes the need for such governmental entities to audit and evaluate the Part 2 programs for compliance with applicable laws, rules, regulations and policies. SAMHSA also recognizes the

practical need for such governmental entities to hire contractors, subcontractors and legal representatives to conduct audits and evaluations on their behalf.

In the final rule, SAMHSA clarifies that federal, state and local governmental entities may receive Part 2-protected patient identifying information directly from the lawful holder when auditing or evaluating a Part 2 program. Patient consent is not required for this purpose or for further redisclosure by the governmental entity to a contractor, subcontractor or legal representative to conduct the audit or evaluation. As with any disclosures, Part 2 programs should limit the information to the minimum necessary to accomplish the task.

Subsequent to the 2017 Final Rule, SAMHSA released additional proposed rules on August 26, 2019, relating to the confidentiality of SUD patient records created by certain Part 2 programs. These 2019 proposed rules aimed to balance certain policy interests by allowing providers to share patients' care records for treatment purposes while still respecting the privacy concerns of patients who are seeking treatment. Some highlights from the 2019 proposed rule are as follows:

- Information that a non-Part 2 provider records in writing about a patient's SUD or SUD treatment is not automatically a Part 2 record as long as those portions are segregated from other SUD information.
- Part 2 programs and lawful holders of SUD records may obtain a consent that identifies the name of the individuals or entities to which SUD information may be disclosed. Previously, only individuals could be consented to, making it challenging to consent to disclosures to agencies or organizations if the recipient's identity was not known.
- Lawful holders may disclose Part 2 SUD records to subcontractors for myriad reasons that largely align with HIPAA definitions for payment and health care operations; however, the 2019 proposed rule makes these reasons illustrative rather than exhaustive.
- Lawful holders of Part 2 information would not be able to redisclose SUD records to third-party case managers or care coordinators pursuant to an individual's billing consent. The proposed rule clarifies that case management and care coordination are forms of treatment rather than health care operations.
- Lawful holders and Part 2 programs that also happen to be HIPAA covered entities or business associates would be able to disclose Part 2 SUD records for research purposes pursuant to the HIPAA research disclosure pathways and to researchers who are subject to FDA regulations on human subjects research. This change would broaden the categories of individual who could conduct research on Part 2 patient identifying information.
- Any health care provider with a treating relationship would be able to query opioid treatment program registries (e.g., prescription drug monitoring programs (PDMP)) to determine whether the patient is receiving medication-assisted treatment, such as methadone, prior to referring such patients to another opioid treatment program. Currently, Part 2 does not permit opioid treatment programs to report methadone or buprenorphine dispensing information to PDMPs, but the proposed rule would allow such disclosure upon patients' consent.

The proposed rule has not been finalized, yet, so it remains to be seen whether any of these changes will be implemented and how they will align with the previous revisions. There is also regular bipartisan push in Congress to align Part 2 with HIPAA to allow safer, more effective and better-coordinated treatment for patients with SUD.

#### **IV. California Consumer Privacy Act of 2018**

On June 28, 2018 California passed the [California Consumer Privacy Act of 2018](#) (CCPA), which went into effect as of January 1, 2020. It is one of the strictest privacy laws in the country, and has parallels to the EU's GDPR. The CCPA broadly governs the collection, use and sharing of California residents', households and devices. It also grants consumers a private right of action for data security breaches and a right to request a business to disclose the categories and specific pieces of information that it collects about the consumer, where it gets personal information, the business purpose for collecting or selling personal information, and with whom that information is shared.

The California Attorney General is tasked with enforcing compliance and has released [proposed regulations](#) to give more color and context on how enforcement will proceed. These regulations are unlikely to take effect until October 2020 – and possibly not until 2021 – although the Attorney General began enforcing the CCPA starting on July 1, 2020. Specific details of the CCPA are as follows:

- **Who is subject to the CCPA?**
  - The CCPA applies to **for-profit** entities “doing business” in California in addition to companies physically located in California (including parent/subsidiaries that share common branding) that:
    - Have a gross annual revenue in excess of \$25 million;
    - Annually buy, receive, sell or share personal information of 50,000 or more California residents, households or devices for commercial purposes;
    - OR
    - Experience more than 50% of their annual revenues from selling California residents' personal information.
- **What Personal Information is protected by CCPA?**
  - Personal information includes information that identifies, relates to, describes, is capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular consumer or household.
  - Examples include:
    - Identifiers such as a real name, alias, postal address, unique personal identifier, online identifier, Internet Protocol address, email address, account name, social security number, driver's license number, passport number, or other similar identifiers;
    - Characteristics of protected classifications under California or federal law;
    - Commercial information, including records of personal property, products or services purchased, obtained, or considered, or other purchasing or consuming histories or tendencies;
    - Biometric information;

- Internet or other electronic network activity information, including, but not limited to, browsing history, search history, and information regarding a consumer’s interaction with an Internet Website, application, or advertisement;
  - Geolocation data;
  - Audio, electronic, visual, thermal, olfactory, or similar information;
  - Professional or employment-related information;
  - Education information, defined as information that is not publicly available personally identifiable information as defined in the Family Educational Rights and Privacy Act;
  - Inferences drawn from any of the information above to create a profile about a consumer reflecting the consumer’s preferences, characteristics, psychological trends, preferences, predispositions, behavior, attitudes, intelligence, abilities, and aptitudes.
- **What must companies do to comply with CCPA?**
  - Companies must post a privacy notice that lists:
    - The categories of personal information collected, sources of personal information, and the purposes for collecting;
    - The categories of personal information sold or disclosed by the company, the purposes for the disclosure, and the categories of third parties;  
AND
    - Consumers’ rights under the CCPA to (i) access a copy of their personal information, (ii) delete their personal information (iii) opt-out of the sale of their personal information; and (iv) have a right to non-discrimination for exercising any of their consumer rights.
    - The privacy notice must also describe methods by which consumers can exercise their rights.
  - Companies must implement policies and procedures addressing their plan for responding to consumer rights requests
    - Companies must respond to customer requests for information about the personal information that has been collected by detailing:
      - the categories of all personal information that have been collected online or offline;
      - the sources from which the information was collected;
      - the business purposes for collecting;
      - the categories of third parties that info is shared with (including vendors and service providers); and
      - the specific pieces of personal information collected about the customer.
    - Policies should address the mechanisms with which California residents may make requests, verification procedures for the requests, how requests are tracked and documented, how requests for exemptions are addressed, and how consumer information is securely shared with consumers and/or deleted within the company’s system.
    - The policies should also address how consumers can opt-out of the sale of their personal information.

- **Are there any other nuances that companies and consumers should know?**
  - Customer requests for this information must be accepted online and by phone and the customer must be responded to through a customer's "account", or if they do not have an account, by mail or electronically at customer's option. Electronically formatted responses must be in a "readily useable format" so the data can be transferred to another entity.
  - Customers have right to request deletion of any personal information that has been collected, with only narrow exceptions. When responding to a customer deletion request, the company must direct vendors to delete any personal information from their records.
  - If company sells or shares personal information (including with vendors or service providers for business purposes) it must:
    - Respond to customer requests with details about personal information sold/shared, and categories of third parties sold to/shared with
    - Offer customers the ability to opt-out of sales of personal info (n/a to sharing for business purpose)
    - If information is sold, companies must have a "do not sell my information" link on their homepage and a publicly available webpage providing details about selling information and opting out.
  - Consumers have a limited private right of action for any unauthorized access and exfiltration, theft or disclosure of nonencrypted and nonredacted personal information that arises due to a business's failure to implement and maintain reasonable security procedures and practices appropriate for the type of personal information.
    - Protected personal information that may give rise to this private right of action includes:
      - Social security number
      - Driver's license number or California ID card number
      - Account number, credit card or debit card number in combination with any required security code, access code, or password that would allow access to a consumer's financial account;
      - Medical information

OR

      - Health insurance information
    - Remedies include
      - Actual damages; or
      - Statutory damages of not less than \$100 and not greater than \$750 per consumer per incident.
      - Injunctive or declaratory relief.
    - A consumer must allege in writing the specific violations. Companies then have a 30-day cure period before any individual or class action for statutory damages can proceed.
  - The California Privacy Rights Act will likely be a November 2020 ballot initiative pending certification of signatures. If passed, this act would create new privacy obligations and introduce more protective measures for California residents' personal information.

## V. Cyber Security Tips and Considerations

### 1) Data Security Generally

- a. Also called Information Security or Cybersecurity
  - i. As opposed to physical security, which is also important, but which is well understood
- b. Data security is of the utmost importance, whether or not you access, store or process regulated data (PHI, PII).
  - i. For lawyers & organizations, Data Security must be baked in to everything, especially if you're dealing with regulated data like Patient Health Information.
- c. "Data Security is a journey, not a destination."
  - i. It's not about installing one security product or doing a security audit or assessment every so often. Those things can help, but they may not be enough.
  - ii. It helps to install the right software tools that help maintain data security, but also important to use them the right way with consistent processes.

### 2) Organizational Data Security

- a. If you're big enough to employ IT professionals,
  - i. Best to have staff dedicated to data security. A Chief Information Security Office (CISO), if possible.
  - ii. Whether dedicated or not, your IT team should keep up with evolving security best practices, and it should be a major component of their job.
- b. If you're not big enough to have an IT department,
  - i. You have to rely on vendors to keep you secure.
  - ii. Well known vendors are more likely to have high quality data security practices.
- c. It's helpful/required to have consistent policies & procedures, about which employees are educated.
- d. It's helpful/required to have an Incident Response Plan that includes potential for Cyber-related incidents
  - i. E.g., do you know how to react if/when you have a breach of regulated data?
  - ii. See Attachment D for a sample letter notifying individuals of a breach of their personal information.
- e. It's helpful/required to have an inventory of all systems & locations where regulated data may be stored or processed.
  - i. Sometimes called "Data Maps"
  - ii. Enables a systematic process for evaluating security of regulated data throughout your organization.
  - iii. Include systems whether regulated data is "in transit" (email) or "at rest" (databases, hard drives)
- f. It's helpful/required to perform regular/annual data security risk assessments
  - i. Use your data maps to review the data security and related processes.
  - ii. If/when you find shortcomings, make a plan to remediate the problems.

### 3) Vendor Data Security

- a. You are more than likely relying on some kind of third party to store or process sensitive data.
  - i. Gmail, Google Docs, Office 365 all use the Internet or “the Cloud”
  - ii. Well-known cloud and Software-as-a-Service (SaaS) vendors are more likely to use the latest best practices for data security.
  - iii. Less well-known cloud and SaaS vendors should be investigated for security practices.
    - 1. *Do they have a SOC 2 report for their data center?*
    - 2. *For HIPAA, will they sign a Business Associate Agreement (BAA)?*
- b. For regulated data, use vendors who explicitly state they are secure.
  - i. For example, “HIPAA Compliant Security” or “HITRUST Certified”
    - 1. *No specific certification authorized under HIPAA, but HITRUST is an industry-driven certification that comes close.*
  - ii. Be prepared to potentially audit your vendors’ security practices.

### 4) Personal Data Security

- a. Regardless of size or type of organization, we all need to be responsible for our own personal data security
- b. Two-Factor Authentication
  - i. Use two-factor authentication wherever it’s offered.
  - ii. In general, logging in always requires you to provide:
    - 1. *something you know (like a password or a pin code),*
    - 2. *something you are (your face, your fingerprint), or*
    - 3. *something you have (your phone, a key).*
  - iii. Two factor (or sometimes called multi-factor) requires that you provide something from at least two of these categories, like a code texted to your phone, in addition to your account password.
  - iv. Especially for accounts & websites that access regulated data (PHI or PII), financial (a bank), or are closely tied to your identity or your organization’s identity (e.g., Facebook, Google, Twitter, LinkedIn)
  - v. Using a code from an authenticator app (e.g., Google Authenticator) or a hardware authenticator is better than a code texted to your phone, but any two-factor is better than no two-factor
- c. Passwords & Password Managers
  - i. Don’t reuse passwords and use a password manager
  - ii. Reusing passwords makes it easy for hackers to break into other sites if they happen to get access to one site’s passwords, which happens far too often.
  - iii. A reputable Password Manager (e.g., LastPass, 1Password) installs on all your devices, syncs across those devices, and acts as a secure storage locker for all your passwords, so you don’t have to remember them all, just the main password for your password manager.
  - iv. A Password Manager can also generate different complex passwords for each account, and since you use the Password Manager to retrieve them each time you log in, you don’t have to remember them.
- d. Hard Drive Encryption
  - i. Encrypt your hard drive

- 1. Turn on BitLocker on Windows machines*
  - 2. Turn on FileVault on Mac machines*
- ii. Encrypting your hard drive makes it virtually impossible for someone to access your files in the situation where your computer is lost or stolen.

## Business Associate Agreement

This **BUSINESS ASSOCIATE AGREEMENT** (this “**Agreement**”) is effective as of [Month, Day, Year] (the “**Effective Date**”). For purposes of this Agreement, [Insert Name] shall be referred to herein as the “**Covered Entity**” and [Insert Name] shall be referred to herein as the “**Business Associate**.”

### **RECITALS**

**WHEREAS**, the Covered Entity and the Business Associate have entered into an arrangement whereby the Business Associate provides certain specified services to the Covered Entity;

**WHEREAS**, the Covered Entity may need to disclose information to the Business Associate, some of which may constitute Protected Health Information; and

**WHEREAS**, it is the mutual intent of the Covered Entity and the Business Associate to execute this Agreement in order for the Covered Entity to remain in compliance with HIPAA.

**NOW THEREFORE**, in consideration of the mutual agreements, covenants, terms and conditions herein contained, the parties hereto agree as follows:

### **1. GENERAL PROVISIONS**

1.1 **Effect.** The provisions of this Agreement shall control with respect to Protected Health Information that Business Associate receives from or on behalf of the Covered Entity.

1.2 **No Third Party Beneficiaries.** The Parties have not created and do not intend to create by this Agreement any third party rights.

1.3 **Defined Terms.** Capitalized terms used in this Agreement that are not defined shall have the respective meanings assigned to such terms in the Administrative Simplification section of the Health Insurance Portability and Accountability Act of 1996, as amended, and its implementing regulations (45 C.F.R. parts 160-164) (collectively, “**HIPAA**”).

### **2. OBLIGATIONS OF THE BUSINESS ASSOCIATE**

2.1 **Use and Disclosure of Protected Health Information.** Business Associate may use and disclose Protected Health Information as permitted or required under this Agreement as set forth herein or on Schedule 2.1 attached here, and as otherwise Required by Law, but shall not otherwise use or disclose any Protected Health Information. Business Associate is permitted to use or disclose Protected Health Information as set forth below:

(a) Business Associate may use Protected Health Information internally for Business Associate’s proper management and administrative services or to carry out its legal responsibilities, and as authorized by this Agreement.

(b) Business Associate may disclose Protected Health Information to third parties for Business Associate’s proper management and administration, provided, however, that if a disclosure is Required by Law, or Business Associate obtains reasonable assurances from the person to whom the information is to be disclosed that it will be held confidentially and be used or further disclosed only as Required by Law or for the purpose for which it was disclosed to the

person, and the person is required to notify Business Associate of any instances of which the person is aware in which the confidentiality of the information has been breached.

(c) Business Associate may use Protected Health Information to provide Data Aggregation services as defined by HIPAA, which shall include Business Associate and its designated subcontractors taking steps to de-identify Protected Health Information, consistent with applicable HIPAA requirements.

2.2 **Safeguards.** Business Associate shall use reasonable administrative, technical and physical safeguards to prevent the use or disclosure of Protected Health Information, except as otherwise permitted or required by this Agreement. In addition, Business Associate shall implement administrative, physical and technical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of Electronic Protected Health Information that it creates, receives, maintains or transmits on behalf of the Covered Entity.

2.3 **Agreements by Third Parties.** Except as otherwise permitted by Section 2.1, Business Associate shall obtain and maintain an agreement with each agent or subcontractor that has or will have access to Protected Health Information, which is received from, or created or received by Business Associate on behalf of the Covered Entity, pursuant to which agreement such agent or subcontractor agrees to be bound by the same restrictions, terms and conditions that apply to Business Associate pursuant to this Agreement with respect to such Protected Health Information.

2.4 **Reporting of Improper Disclosures of Protected Health Information.** As soon as practicable after Business Associate becomes aware of any use or disclosure of Protected Health Information in violation of the Agreement by Business Associate, its officers, directors, employees, contractors or agents or by a third party to which Business Associate disclosed Protected Health Information, Business Associate shall report any such use or disclosure to the Covered Entity. In addition, Business Associate shall report any security incidents involving related Protected Health Information of which it becomes aware in the following manner: (i) any actual, successful security incident will be reported to the Covered Entity in writing as soon as practicable, and (ii) any attempted, unsuccessful security incident of which the Business Associate becomes aware will be reported to the Covered Entity orally or in writing on a reasonable basis, as requested by the Covered Entity. If the security regulations under HIPAA are amended to remove the requirement to report unsuccessful attempts at unauthorized access, this requirement will no longer apply as of the effective date of that amendment.

2.5 **Access to Information.** Within fifteen (15) business days of a written request by the Covered Entity for access to Protected Health Information about an Individual contained in any Designated Record Set of the Covered Entity maintained by Business Associate, if any, Business Associate shall make available to the Covered Entity such Protected Health Information for so long as Business Associate maintains such information in the Designated Record Set.

2.6 **Availability of Protected Health Information for Amendment.** Within fifteen (15) business days of receipt of a written request from the Covered Entity for the amendment of an Individual's Protected Health Information contained in any Designated Record Set of the Covered Entity maintained by Business Associate, if any, Business Associate shall provide such information to the Covered Entity for amendment and incorporate any such amendments in the

Protected Health Information (for so long as Business Associate maintains such information in the Designated Record Set) as required by 45 C.F.R. §164.526.

2.7 **Accounting of Disclosures.** Within fifteen (15) business days of written notice by the Covered Entity to Business Associate that it has received a request for an accounting of disclosures of Protected Health Information (other than disclosures to which an exception to the accounting requirement applies), Business Associate shall make available to the Covered Entity such information as is in Business Associate's possession and is required for the Covered Entity to make the accounting required by 45 C.F.R. §164.528.

2.8 **Availability of Books and Records.** Following reasonable advance written notice, Business Associate shall make its internal practices, books and records relating to the use and disclosure of Protected Health Information received from, or created or received by Business Associate on behalf of, the Covered Entity available to the Secretary for purposes of determining the Covered Entity's compliance with HIPAA.

### 3. **TERMINATION OF THE AGREEMENT.**

3.1 **Termination Upon Breach of Provisions Applicable to Protected Health Information.** Any implied or express agreements, relating to Protected Health Information, between the Covered Entity and the Business Associate may be terminated by the Covered Entity upon thirty (30) days written notice to Business Associate in the event that Business Associate breaches any provision contained in this Agreement in any material respect and such breach is not cured within such thirty (30) day period.

3.2 **Destruction of Protected Health Information upon Termination.** Upon termination of any such implied or express agreements referenced in Section 3.1, Business Associate shall either return to Covered Entity or destroy all Protected Health Information received from the Covered Entity or created or received by Business Associate on behalf of the Covered Entity and which Business Associate still maintains as Protected Health Information. Notwithstanding the foregoing, to the extent that Business Associate reasonably and in good faith determines that it is neither feasible to return or destroy such Protected Health Information, the terms and provisions of this Agreement shall survive termination of any implied or express agreements referenced in Section 3.1 and such Protected Health Information shall be used or disclosed solely for such purpose or purposes which prevented the return or destruction of such Protected Health Information.

### 4. **OBLIGATIONS OF THE COVERED ENTITY.**

4.1 **Permissible Requests.** The Covered Entity shall not request Business Associate to use or disclose Protected Health Information in any manner that would not be permissible under HIPAA if done directly by the Covered Entity.

*<Signatures to Follow on Next Page>*

**IN WITNESS WHEREOF**, each of the parties has caused this Agreement to be executed by its duly authorized representative as of the Effective Date.

<b>[Business Associate]</b>	<b>[Covered Entity]</b>
By: _____	By: _____
Print Name: _____	Print Name: _____
Title: _____	Title: _____

Schedule 2.1

Description of Services to be Provided by Business Associate to Covered Entity

Appendix B

**CONSENT FOR THE RELEASE OF CONFIDENTIAL SUBSTANCE USE DISORDER  
TREATMENT INFORMATION**

**Instructions:** Please read this consent form in its entirety before proceeding. Your consent allows \_\_\_\_\_ to release your substance use disorder treatment information to individual(s) or organization(s) you specifically name. Please provide the requested information on the spaces below. **The form must be signed and dated for authorization.**

Name: \_\_\_\_\_

I authorize \_\_\_\_\_ (insert name or general designation of individual or program) to release the following information (check all that apply):

- From dates: \_\_\_\_\_ to \_\_\_\_\_:  All my substance use disorder treatment information;  
 Medication(s) only;  Physician's Order(s);  Progress Notes;  Laboratory/Diagnostic Studies;  
 Plan(s) of Care;  Discharge Summary(ies);  Other (please specify): \_\_\_\_\_

\_\_\_\_\_ to the following individual(s) or organization(s) (attach a separate sheet if necessary):

- Individual (E.g., Treating provider or any specifically named individual, e.g. spouse, parent, child):  
\_\_\_\_\_  
\_\_\_\_\_

- Organization/Facility with which Patient has a Treating Provider Relationship (Name of Org.): \_\_\_\_\_  
\_\_\_\_\_

- Insurance Provider (Name of Payor):  
\_\_\_\_\_

- Research Institution (Name of Institution):  
\_\_\_\_\_

- \_\_\_\_\_ AND  
 Name(s) of individual(s) at Institution: \_\_\_\_\_ OR  
 Name(s) of organization(s) with a treating provider relationship: \_\_\_\_\_ OR  
 To all my treating providers who participate in the Institution, past, present and future  
 If you elect to disclose information to all your treating providers, past and present, you have the right to request that \_\_\_\_\_ provide you with a list of entities to which your information has been disclosed for the last two years. (If you elect this designation, please check the box to the left confirming that you understand that you may ask for this list of disclosures at any time.)

**For further disclosure to:**

- Name(s) of individual(s): \_\_\_\_\_ OR  
 Name(s) of organization(s) with a treating provider relationship: \_\_\_\_\_ OR  
 To all my treating providers, past, present and future  
 If you elect to disclose information to all your treating providers, past and present, you have the right to request that \_\_\_\_\_ give you a list of entities to which your information has been disclosed

for the last two years. *(If you elect this designation, please check the box to the left confirming that you understand that you may ask for this list of disclosures at any time.)*

**For the limited purpose of** *(circle any or insert purpose):*

- Treatment**
- Care coordination**
- For billing purposes**
- To provide an update about my status to specifically named individual(s)/organization(s) listed above**
- Other reason(s):** \_\_\_\_\_  
\_\_\_\_\_

---

**I also understand that I may revoke this consent at any time (verbally or in writing) except to the extent that any action was taken in reliance on it.**

If not previously revoked, this consent will expire on/when/if (add date or event): \_\_\_\_\_ **OR**  
\_\_\_\_\_ one year from today's date, whichever is earlier.

**Signature** *(or individual authorized to give consent and sign):*

\_\_\_\_\_

**Date:**

\_\_\_\_\_

I understand that any records relating to treatment of a substance use disorder are protected under federal regulations governing Confidentiality of Substance Use Disorder Patient Records, 42 C.F.R Part 2, and 45 C.F.R Parts 160 and 164, as well as **[insert applicable State laws]** and cannot be disclosed without my written consent unless otherwise provided for in the law.

## Appendix C

### **NOTICE TO PARTY RECEIVING SUBSTANCE USE DISORDER INFORMATION**

This information has been disclosed to you from records protected by Federal confidentiality rules (42 C.F.R Part 2). The Federal rules prohibit you from making any further disclosure of information in this record that identifies a patient as having or having had a substance use disorder either directly, by reference to publicly available information, or through verification of such identification by another person unless further disclosure is expressly permitted by the written consent of the individual whose information is being disclosed or as otherwise permitted by 42 C.F.R Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The federal rules restrict any use of the information to investigate or prosecute with regard to a crime any patient with a substance use disorder, except as provided at 42 C.F.R §2.12(c)(5) and §2.65.

Appendix D

Breach Notification Letter

[DATE]

***Important Security and Protection Notification. Please read this entire letter.***

Dear \_\_\_\_\_

[WE] recently learned that the security of certain of our information systems was compromised by a criminal cyber attack apparently designed to collect Social Security numbers, credit card numbers and other financial information. Between [DATE RANGE] our forensic investigators confirmed that this attack potentially exposed certain of your information to unauthorized access and acquisition. I say “potentially” because, to date, there is no evidence that any information was actually accessed or acquired as a result of this criminal invasion. However, the information potentially exposed may have included your name, contact information, medical or healthcare information, date of birth, credit card information, Social Security number and health insurance account number. Based upon our investigation, the period during which your information may have been exposed appears to have been between [DATE RANGE].

Out of an abundance of caution, we want to make you aware of the attack and our efforts to help safeguard your information. Immediately upon learning of this criminal attack and the potential exposure of private patient information, [WE] took action. Specifically, upon learning of the potential of this incident, we promptly took the following actions: (i) curtailed the intrusion; (ii) hired numerous experts, including two leading national forensic investigation firms, to help us investigate the situation and determine the individuals and information potentially affected; and (iii) began the process of notifying potentially affected individuals. In addition, we have notified law enforcement and are taking steps to further guard against this type of criminal attack in the future.

As always, we recommend that you remain vigilant by reviewing your explanation of benefits for medical services and financial account statements, as well as free credit reports for unauthorized activity. From the moment we learned of the potential exposure, our primary concern has been ensuring that you are protected against risks related to this incident. Therefore, we have engaged \_\_\_\_\_, one of the leading providers of credit monitoring products, to provide you with its \_\_\_\_\_, including credit monitoring, for one year at no cost to you. Enclosed with this letter is information regarding these services and instructions for enrollment, as well as an insert providing additional useful information regarding steps you can take to protect yourself against identity theft. We have also engaged \_\_\_\_\_ to provide a dedicated call center to answer questions about this incident. If you have any questions regarding this incident or would like assistance enrolling in \_\_\_\_\_, please contact \_\_\_\_\_.

We take your privacy very seriously. We sincerely regret that this unfortunate attack occurred and we apologize for any inconvenience or concern it may cause you. We value our relationship with you and remain committed to serving the needs of our community.